CA
NZ
UK
AU
IND
US
BridgeBio Pharma (NASDAQ:BBIO) traded at US$66.50 as of 8 October 2026, against an analyst consensus price target of US$106.95, an implied upside of approximately +60.8%.
Biogen (NASDAQ:BIIB) traded at US$222.15 as of 8 October 2026, against an analyst consensus price target of US$229.84, an implied upside of approximately N/A.
BioMarin (NASDAQ:BMRN) traded at US$55.20 as of 8 October 2026, against an analyst consensus price target of US$89.52, an implied upside of approximately +62.2%.
BioNTech (NASDAQ:BNTX) traded at US$95.25 as of 8 October 2026, against an analyst consensus price target of US$123.79, an implied upside of approximately +30.0%.
BrightSpring Health Services (NASDAQ:BTSG) traded at US$63.80 as of 8 October 2026, against an analyst consensus price target of US$71.53, an implied upside of approximately +12.1%.
● The round backs an early-stage life-sciences business.
● The deal covers DevOps and agentic-AI tooling.
● Oculis signed an asset purchase agreement for Privosegtor (ACT-01) and a preclinical candidate, ACT-02.
●Net Incomewas $15.7 million, against a $43.7 million loss a year earlier.
● Second-quarterRevenuewas $343,639, up from $56,325 in the first quarter.
Please wait processing your request...